Показано 0 из 0
Дата |
---|
18.03.2024 |
15.03.2024 |
14.03.2024 |
13.03.2024 |
12.03.2024 |
11.03.2024 |
08.03.2024 |
07.03.2024 |
06.03.2024 |
05.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.32
|
0.3399
|
0.323
|
0.28
|
0.3498
|
0.333
|
|
|
100 328.59
|
1 193.00
|
0.35
|
0.351
|
0.2745
|
0.2745
|
0.3888
|
0.345
|
|
|
1 736 515.62
|
12 862.00
|
4.92
|
5.00
|
4.95
|
4.94
|
4.99
|
4.98
|
|
|
191 075.73
|
138.00
|
4.93
|
4.96
|
4.95
|
4.93
|
4.97
|
4.95
|
|
|
84 546.13
|
89.00
|
4.94
|
4.96
|
4.93
|
4.92
|
4.965
|
4.95
|
|
|
205 668.16
|
203.00
|
4.91
|
4.95
|
4.96
|
4.91
|
4.96
|
4.92
|
|
|
214 924.47
|
174.00
|
4.91
|
4.94
|
4.93
|
4.90
|
4.96
|
4.925
|
|
|
436 536.01
|
228.00
|
4.87
|
4.95
|
4.91
|
4.89
|
4.92
|
4.89
|
|
|
398 328.68
|
196.00
|
4.91
|
4.95
|
4.90
|
4.895
|
4.945
|
4.94
|
|
|
195 119.63
|
105.00
|
4.87
|
4.96
|
4.89
|
4.89
|
4.92
|
4.90
|
|
|
182 527.30
|
94.00
|
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.